Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Oncolytic viruses for the treatment of neuroendocrine tumors.

Essand M, Leja J, Giandomenico V, Oberg KE.

Horm Metab Res. 2011 Nov;43(12):877-83. doi: 10.1055/s-0031-1277225. Epub 2011 May 30. Review.

PMID:
21626470
2.

Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.

Leja J, Yu D, Nilsson B, Gedda L, Zieba A, Hakkarainen T, Åkerström G, Öberg K, Giandomenico V, Essand M.

Gene Ther. 2011 Nov;18(11):1052-62. doi: 10.1038/gt.2011.54. Epub 2011 Apr 14.

PMID:
21490682
3.

Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14.

Wang H, Li ZY, Liu Y, Persson J, Beyer I, Möller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, Wahl JK 3rd, Urban N, Drescher C, Hemminki A, Fender P, Lieber A.

Nat Med. 2011 Jan;17(1):96-104. doi: 10.1038/nm.2270. Epub 2010 Dec 12.

4.

Varying opinions on the authenticity of a human midgut carcinoid cell line--letter.

Ellis LM, Samuel S, Sceusi E.

Clin Cancer Res. 2010 Nov 1;16(21):5365-6. doi: 10.1158/1078-0432.CCR-10-2550. Epub 2010 Oct 19. No abstract available.

5.

Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy.

Thorne SH, Liang W, Sampath P, Schmidt T, Sikorski R, Beilhack A, Contag CH.

Mol Ther. 2010 Sep;18(9):1698-705. doi: 10.1038/mt.2010.140. Epub 2010 Jul 6.

6.

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y.

Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15.

7.

Intracellular transduction using cell-penetrating peptides.

Sawant R, Torchilin V.

Mol Biosyst. 2010 Apr;6(4):628-40. doi: 10.1039/b916297f. Epub 2009 Dec 21. Review.

PMID:
20237640
8.

Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors.

Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V, Kangasniemi L, Laasonen L, Ribacka C, Guse K, Haavisto E, Oksanen M, Rajecki M, Helminen A, Ristimäki A, Karioja-Kallio A, Karli E, Kantola T, Bauerschmitz G, Kanerva A, Joensuu T, Hemminki A.

Gene Ther. 2010 Jul;17(7):892-904. doi: 10.1038/gt.2010.17. Epub 2010 Mar 18.

PMID:
20237509
9.

An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood.

Danielsson A, Elgue G, Nilsson BM, Nilsson B, Lambris JD, Tötterman TH, Kochanek S, Kreppel F, Essand M.

Gene Ther. 2010 Jun;17(6):752-62. doi: 10.1038/gt.2010.18. Epub 2010 Mar 11.

PMID:
20220781
10.

Secondary structure of cell-penetrating peptides controls membrane interaction and insertion.

Eiríksdóttir E, Konate K, Langel U, Divita G, Deshayes S.

Biochim Biophys Acta. 2010 Jun;1798(6):1119-28. doi: 10.1016/j.bbamem.2010.03.005. Epub 2010 Mar 7.

11.

Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability.

Leja J, Nilsson B, Yu D, Gustafson E, Akerström G, Oberg K, Giandomenico V, Essand M.

PLoS One. 2010 Jan 27;5(1):e8916. doi: 10.1371/journal.pone.0008916.

12.

Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy.

Zhang YQ, Tsai YC, Monie A, Wu TC, Hung CF.

Mol Ther. 2010 Apr;18(4):692-9. doi: 10.1038/mt.2009.318. Epub 2010 Jan 19.

13.

Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence.

Rebetz J, Na M, Su C, Holmqvist B, Edqvist A, Nyberg C, Widegren B, Salford LG, Sjögren HO, Arnberg N, Qian Q, Fan X.

PLoS One. 2009 Dec 29;4(12):e8484. doi: 10.1371/journal.pone.0008484.

14.

Adenovirus-mediated cancer gene therapy and virotherapy (Review).

Fukazawa T, Matsuoka J, Yamatsuji T, Maeda Y, Durbin ML, Naomoto Y.

Int J Mol Med. 2010 Jan;25(1):3-10. Review.

PMID:
19956895
15.

Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus-based vectors.

Seregin SS, Amalfitano A.

Expert Opin Biol Ther. 2009 Dec;9(12):1521-31. doi: 10.1517/14712590903307388. Review.

PMID:
19780714
16.

Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus.

Shashkova EV, May SM, Doronin K, Barry MA.

Mol Ther. 2009 Dec;17(12):2121-30. doi: 10.1038/mt.2009.217. Epub 2009 Sep 15.

17.

Improved gene transfer into renal carcinoma cells using adenovirus vector containing RGD motif.

Terao S, Acharya B, Suzuki T, Aoi T, Naoe M, Hamada K, Mizuguchi H, Gotoh A.

Anticancer Res. 2009 Aug;29(8):2997-3001.

18.

Transduction of adenovirus vectors modified with cell-penetrating peptides.

Eto Y, Yoshioka Y, Asavatanabodee R, Kida S, Maeda M, Mukai Y, Mizuguchi H, Kawasaki K, Okada N, Nakagawa S.

Peptides. 2009 Aug;30(8):1548-52. doi: 10.1016/j.peptides.2009.05.017. Epub 2009 May 23.

PMID:
19467282
19.

Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Alba R, Bradshaw AC, Parker AL, Bhella D, Waddington SN, Nicklin SA, van Rooijen N, Custers J, Goudsmit J, Barouch DH, McVey JH, Baker AH.

Blood. 2009 Jul 30;114(5):965-71. doi: 10.1182/blood-2009-03-208835. Epub 2009 May 8.

20.

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.

Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW.

Biotechniques. 2008 Dec;45(6):659-62, 664-8.

PMID:
19238796

Supplemental Content

Support Center